目前的 ELISA 方法检测血清 suPAR 是否为 FSGS 的可靠诊断生物标志物？
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
机构信息
Mount Sinai School of Medicine, New York, New York, USA.
出版信息
Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.
A soluble proteinuric substance has been postulated as a cause of primary focal segmental glomerulosclerosis (FSGS), and one candidate soluble urokinase receptor (suPAR). Evaluation of published results shows that serum suPAR determinations by current methodology do not reliably distinguish FSGS from other proteinuric glomerular diseases and serum suPAR cannot currently be considered a valid biomarker for primary or secondary FSGS. However, this should not discourage further research on potential roles of suPAR in proteinuric renal disease, including FSGS.
一种可溶的蛋白尿物质被假定为原发性局灶节段性肾小球硬化症（FSGS）的病因，其中一个候选物是可溶性尿激酶受体（suPAR）。对已发表结果的评估表明，当前方法学测定的血清 suPAR 并不能可靠地区分 FSGS 与其他蛋白尿性肾小球疾病，并且血清 suPAR 目前不能被视为原发性或继发性 FSGS 的有效生物标志物。然而，这不应阻止进一步研究 suPAR 在蛋白尿性肾脏疾病（包括 FSGS）中的潜在作用。
Zotero 插件